Genovis: USD139m sublicensing to Astellas Pharma - Redeye

Redeye comments on Genovis following today's news regarding a sublicensing of Xork to Astellas Pharma worth up to USD139m, with USD4m upfront. The optionality in the case again shines through and pinpoints the application heterogeneity for Genovis's enzymes and further reinforces our positive take on the case. We will return with an updated assessment and raised fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/870436/genovis-usd139m-sublicensing-to-astellas-pharma?utm_source=finwire&utm_medium=RSS